Welcome to Sanofi Rare Blood Disorders. Here you'll find information about our therapies along with helpful resources and patient resources.
Driven by curiosity, guided by science. Learn more about Sanofi Rare Blood Disorders therapies.
Contact a Representative
Need more information? Sign up to schedule an office visit with a Sanofi Representative.
SCHEDULE A VISITThis site is intended for U.S. Healthcare Professionals only.
© 2024 Sanofi. All rights reserved.
Sanofi is a registered trademark of Sanofi or an affiliate.
All other trademarks are the property of their respective owners.
MAT-US-2309562-v4.0-07/2024
Now approved
Please See Full Prescribing Information.
ALTUVIIIO is contraindicated in patients who have had severe hypersensitivity reactions, including anaphylaxis, to the product or its excipients.
The most common adverse reactions (>10% of subjects) reported in clinical trials were headache and arthralgia.
ALTUVIIIO®[antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is a von Willebrand Factor (VWF) independent recombinant DNA-derived, Factor VIII concentrate indicated for use in adults and children with hemophilia A (congenital factor VIII deficiency) for:
ALTUVIIIO is not indicated for the treatment of von Willebrand disease.
Please see full Prescribing Information.
© 2023 Genzyme Corporation. All rights reserved. ALTUVIIIO and
Sanofi are trademarks of Sanofi or an affiliate.
MAT-US-2300535-v1.0-03/2023